Hypophosphatasia

Type: Keyphrase
Name: Hypophosphatasia
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia

-- Application designated for review under accelerated assessmentprocess --CHESHIRE, Conn.--( BUSINESS WIRE )--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that theMarketing Authorization Application (MAA) for asfotase alfa, aninvestigational, ... [Published Business Wire - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 4 reports

European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia

First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Alexion Pharmaceutical To Beat Earnings Again

Alexion Pharmaceuticals, Inc. ( ALXN ) is expected to announce its earnings for the second quarter of the fiscal year 2014 (FY14) on the 24 July, 2014. The company’s earnings per share (EPS) are expected to increase 122.7% to $1.07 for the quarter. The ... [Published Bidness Etc - Jul 23 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

@ISSUE: A bill for every occasion

Lawmakers at the Statehouse need to spend more time addressing the economy, unemployment and other problems that have gone unattended for years.file photoChristie to crunch numbers under Statehouse dome Lawmakers at the Statehouse are too busy waving ... [Published Asbury Park Press - Jul 19 2014]
First reported May 06 2014 - Updated May 06 2014 - 3 reports

New Data Detailing the Devastating Nature of Hypophosphatasia (HPP) and Treatment Effect of Asfotase Alfa in Infants, Young Children and Juveniles with HPP Presented at the Pediatric Academic Societies Meeting

CHESHIRE, Conn.--(EON: Enhanced Online News)--Alexion presented natural history data in patients with severe perinatal & infantile HPP. Early and sustained improvements were observed in infants, children & juveniles receiving asfotase alfa. ... [Published EON Science - May 06 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 3 reports

Researchers to Present New Data on Asfotase Alfa in Infants and Juveniles with Hypophosphatasia at the Joint Meeting of the Pediatric Academic Societies and the Asian Society for Pediatric Research

CHESHIRE, Conn.--(EON: Enhanced Online News)--Alexion announced data from two studies examining long-term efficacy and safety of asfotase alfa in infants and juveniles with hypophosphatasia to be presented at the upcoming PAS and ASPR meeting. ... [Published EON Science - Apr 11 2014]

Quotes

Alexion Pharmaceuticals CEO Leonard Bell said: "Hypophosphatasia is a devastating disease for patients and their families due to progressive deterioration of bones and muscle weakness, which can result in impaired respiratory function, severe disability and death."

More Content

All (14) | News (4) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
EMA accepts Alexion’s marketing authorisation a... [Published Pharmaceutical Technology - Jul 27 2014]
European Medicines Agency Accepts Marketing Aut... [Published Digital Journal - Jul 24 2014]
European Medicines Agency Accepts Marketing Aut... [Published EON Science - Jul 24 2014]
European Medicines Agency Accepts Marketing Aut... [Published Business Wire - Jul 24 2014]
European Medicines Agency Accepts Marketing Aut... [Published Business Wire Science: Science News - Jul 24 2014]
European Medicines Agency Accepts Marketing Aut... [Published Business Wire Health News - Jul 24 2014]
Alexion Pharmaceutical To Beat Earnings Again [Published Bidness Etc - Jul 23 2014]
@ISSUE: A bill for every occasion [Published Asbury Park Press - Jul 19 2014]
New Data Detailing the Devastating Nature of Hy... [Published EON Science - May 06 2014]
New Data Detailing the Devastating Nature of Hy... [Published Business Wire Science: Science News - May 06 2014]
New Data Detailing the Devastating Nature of Hy... [Published Business Wire Health News - May 06 2014]
Researchers to Present New Data on Asfotase Alf... [Published EON Science - Apr 11 2014]
Researchers to Present New Data on Asfotase Alf... [Published Business Wire Science: Science News - Apr 11 2014]
Researchers to Present New Data on Asfotase Alf... [Published Business Wire Health News - Apr 11 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
European Medicines Agency Accepts Marketing Aut... [Published EON Science - Jul 24 2014]
CHESHIRE, Conn.--(EON: Enhanced Online News)--Alexion announced that the marketing authorization application for asfotase alfa has been validated and granted accelerated assessment by the European Medicines Agency. ...
European Medicines Agency Accepts Marketing Aut... [Published Business Wire Science: Science News - Jul 24 2014]
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion announced that the marketing authorization application for asfotase alfa has been validated and granted accelerated assessment by the European Medicines Agency. ...
European Medicines Agency Accepts Marketing Aut... [Published Business Wire Health News - Jul 24 2014]
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion announced that the marketing authorization application for asfotase alfa has been validated and granted accelerated assessment by the European Medicines Agency. ...
New Data Detailing the Devastating Nature of Hy... [Published EON Science - May 06 2014]
CHESHIRE, Conn.--(EON: Enhanced Online News)--Alexion presented natural history data in patients with severe perinatal & infantile HPP. Early and sustained improvements were observed in infants, children & juveniles receiving asfotase alfa. ...
New Data Detailing the Devastating Nature of Hy... [Published Business Wire Science: Science News - May 06 2014]
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion presented natural history data in patients with severe perinatal & infantile HPP. Early and sustained improvements were observed in infants, children & juveniles receiving asfotase alfa. ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.